Imvax, Inc. is a Philadelphia-based biotechnology company specializing in personalized immunotherapies for solid tumors. Leveraging their unique GoldspireTM platform, Imvax captures the complete antigen signature of a tumor to activate the patient's immune system against remaining tumor cells.
With a diverse pipeline of personalized, whole tumor-derived treatments, Imvax has shown promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors, positioning themselves at the forefront of innovative cancer research and treatment.
Generated from the website
